What is LabGenius?
LabGenius is at the forefront of protein engineering, leveraging a proprietary discovery platform named EVATM. This platform uniquely integrates cutting-edge advancements from computer science, robotic automation, and synthetic biology to accelerate the design and development of novel proteins. Headquartered in London, UK, the company's multidisciplinary team comprises experts in protein engineering, synthetic biology, software engineering, data science, and robotic automation, positioning LabGenius as a key innovator in the life sciences industry.
How much funding has LabGenius raised?
LabGenius has raised a total of $73.2M across 3 funding rounds:
Angel/Seed
$3.7M
Series A
$25M
Series B
$44.5M
Angel/Seed (2017): $3.7M with participation from Beast Ventures, Berggruen Holdings, Kindred Capital, Acequia Capital, and System.One.
Series A (2020): $25M led by Inovia Capital, Felicis Ventures, Patrick Pichette, Atomico, Chris Gibson, Lux Capital, Obvious Ventures, and Air Street Capital
Series B (2024): $44.5M supported by M/ventures, Octopus Ventures, and LG
Key Investors in LabGenius
M/ventures
M/ventures is the investment arm of M/CAPITAL PARTNERS, providing funding and guidance to promising startups across various industries, with a focus on supporting entrepreneurs with bold ideas.
Octopus Ventures
Octopus Ventures is a founder-focused venture capital firm that backs mission-driven companies in software, climate, health, consumer, and financial technology, offering long-term capital and support.
LG
LG Corp. is a holding company that manages subsidiaries across various sectors including electronics, chemicals, and telecommunications, with a history dating back to 1947.
What's next for LabGenius?
The substantial enterprise-level funding, particularly the recent strategic investment, positions LabGenius for accelerated growth and further development of its EVATM platform. This capital infusion is expected to fuel expansion into new markets, enhance research and development capabilities, and potentially scale its operations to meet increasing demand for its protein engineering solutions. The company's focus on integrating AI and automation suggests a strategic push towards revolutionizing drug discovery and therapeutic development, aiming to solidify its leadership in the competitive biotech landscape.
See full LabGenius company page
